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Cardiac Biomarkers and Risk of Atrial Fibrillation in Chronic Kidney
Disease: The CRIC Study
Julio A. Lamprea-Montealegre, MD, MPH, PhD; Leila R. Zelnick, PhD; Michael G. Shlipak, MD; James S. Floyd, MD, MS;
Amanda H. Anderson, MPH, PhD; Jiang He, MD, PhD; Rob Christenson, MD; Stephen L. Seliger, MD; Elsayed Z. Soliman, MD; Rajat Deo,
MD; Bonnie Ky, MD, MSCE; Harold I. Feldman, MD, MSCE; John W. Kusek, PhD; Christopher R. deFilippi, MD; Myles S. Wolf, MD;
Tariq Shafi, MD; Alan S. Go, MD; Nisha Bansal, MD, MS; on behalf of the CRIC Study Investigators*
Background-—We tested associations of cardiac biomarkers of myocardial stretch, injury, inflammation, and fibrosis with the risk
of incident atrial fibrillation (AF) in a prospective study of chronic kidney disease patients.
Methods and Results-—The study sample was 3053 participants with chronic kidney disease in the multicenter CRIC (Chronic
Renal Insufficiency Cohort) study who were not identified as having AF at baseline. Cardiac biomarkers, measured at baseline,
were NT-proBNP (N-terminal pro-B-type natriuretic peptide), high-sensitivity troponin T, galectin-3, growth differentiation factor-
15, and soluble ST-2. Incident AF (“AF event”) was defined as a hospitalization for AF. During a median follow-up of 8 years,
279 (9%) participants developed a new AF event. In adjusted models, higher baseline log-transformed NT-proBNP (N-terminal
pro-B-type natriuretic peptide) was associated with incident AF (adjusted hazard ratio [HR] per SD higher concentration: 2.11;
95% CI, 1.75, 2.55), as was log-high-sensitivity troponin T (HR 1.42; 95% CI, 1.20, 1.68). These associations showed a dose–
response relationship in categorical analyses. Although log-soluble ST-2 was associated with AF risk in continuous models (HR
per SD higher concentration 1.35; 95% CI, 1.16, 1.58), this association was not consistent in categorical analyses. Log-galectin-
3 (HR 1.05; 95% CI, 0.91, 1.22) and log-growth differentiation factor-15 (HR 1.16; 95% CI, 0.96, 1.40) were not significantly
associated with incident AF.
Conclusions-—We found strong associations between higher NT-proBNP (N-terminal pro-B-type natriuretic peptide) and high-
sensitivity troponin T concentrations, and the risk of incident AF in a large cohort of participants with chronic kidney disease.
Increased atrial myocardial stretch and myocardial cell injury may be implicated in the high burden of AF in patients with chronic
kidney disease. ( J Am Heart Assoc. 2019;8:e012200. DOI: 10.1161/JAHA.119.012200.)
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A trial fibrillation (AF) is the second most common cardiaccomorbidity in patients with chronic kidney disease
(CKD) 1 observed in 18% of adult CKD patients, an estimate
that is 3-fold higher than in the general population.2 Evidence
from epidemiological studies suggests that CKD is a strong,
independent risk factor for incident AF.3 Furthermore, the
presence of CKD is associated with increased rates of stroke,
bleeding, and death among patients with AF and CKD than
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among patients with normal kidney function.4,5 However, the
pathogenesis of AF in patients with CKD remains poorly
understood.
Atrial myocardial wall stretch and myocardial cell damage
have been implicated in the pathogenesis of AF.6 Cardiac
biomarkers reflecting these pathophysiologic changes have
advanced the understanding of determinants of AF in the
general population. For instance, NT-proBNP (N-terminal pro-
B-type natriuretic peptide), a marker of myocardial wall
stretch, is a strong predictor of AF onset beyond traditional AF
risk factors in the general population.7 Similarly, high-
sensitivity troponin T (hsTnT), a marker of myocardial cell
damage, is also strongly and independently associated with
incident AF in the general population.8 It is possible that the
sustained myocardial wall stress and damage that is common
in CKD may render these patients more susceptible to
developing sustained arrhythmias such as AF.9,10
In addition, myocardial inflammation, fibrosis, and remod-
eling have also been postulated to play a role in the
pathogenesis and perpetuation of AF.6 Consistent with these
possible mechanisms, galectin-3, a beta-galactosidase-bind-
ing lecithin expressed by macrophages that induces fibrosis
and adverse remodeling,11 has been found to be an indepen-
dent predictor of incident AF. In addition, growth-differentia-
tion factor-15 (GDF-15), a growth-factor part of the
transforming growth factor-b cytokine family that increases
in response to myocyte ischemia, stretch, and inflamma-
tion,12–14 and soluble ST2 (SST2), a member of the inter-
leukin-1 receptor family that promotes cardiomyocyte
hypertrophy and fibrosis,15,16 have been shown, to a variable
extent, to be independently associated with AF in the general
population.17,18 In CKD, animal models and human studies
have suggested that even mild impairments in kidney function
lead to accelerated myocardial fibrosis, and have shown a
close link between inflammation and left atrial fibrosis.19–21
The relative contribution of these biologic pathways to AF
have not been well characterized in CKD, where the patho-
physiology of cardiovascular disease is unique.
In this context, evaluation of cardiac biomarkers in patients
with CKD may provide insight into specific mechanistic
pathways by which CKD is associated with AF. In this study,
we evaluated associations of 5 cardiac biomarkers (NT-
proBNP, hsTnT, galectin-3, GDF-15, and SST2) with risk of
incident AF in a large multicenter cohort of men and women
with CKD.
Methods
Study Population
The CRIC (Chronic Renal Insufficiency Cohort) Study is an
ongoing, prospective, multicenter, cohort study of 3939
participants established to examine risk factors for the
progression of CKD and the development and worsening of
cardiovascular disease in patients with CKD.22,23 Adult male
and female patients with CKD aged 21 to 74 years were
eligible to participate if they met the following age-specific
estimated glomerular filtration (eGFR) criteria: 20 to 70 mL/
min per 1.73 m2 for age 21 to 44 years, 20 to 60 mL/min
per 1.73 m2 for age 45 to 64 years, and 20 to 50 mL/min
per 1.73 m2 for age 65 to 74 years. Exclusion criteria
included heart failure (HF) with New York Heart Association
functional class III or IV and polycystic kidney disease.
For this study, we excluded participants who were
identified as having AF at baseline (defined by either self-
report or evidence of AF on a baseline study visit ECG)
(N=666) and participants who were missing at least 1 of the 5
cardiac biomarkers of interest measured (N=220). The final
study population consisted of 3053 participants.
CRIC was approved by the institutional review boards of all
participating institutions. All participants gave written
informed consent before the start of the study. The data that
support the findings of this study are available from the
corresponding author upon reasonable request.
Cardiac Biomarkers
All 5 biomarkers were measured at baseline and at year 2
after cohort entry in duplicate from baseline frozen serum or
plasma samples. NT-proBNP and hsTnT were measured at
baseline in 2008 from EDTA plasma stored at 70°C using a
chemiluminescent microparticle immunoassay (www.roche-
Clinical Perspective
What Is New?
• The mechanism(s) responsible for the increased atrial
fibrillation burden among people with chronic kidney
disease are poorly understood.
• We evaluated associations of cardiac biomarkers of myocar-
dial stretch, injury, inflammation, and fibrosis with risk of
incident atrial fibrillation in a large multicenter cohort of
men and women with chronic kidney disease.
• Cardiac biomarkers of myocardial stretch and injury were
found to be the predominant markers of risk of atrial
fibrillation in people with chronic kidney disease.
What Are the Clinical Implications?
• Our findings provide mechanistic insights into the strong
associations between chronic kidney disease and atrial
fibrillation and may inform future therapeutic trials aimed at
reducing the risk of atrial fibrillation in people with chronic
kidney disease.
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diagnostics.us) on the ElecSys 2010 at the University of
Maryland. The range of values for NT-proBNP was from 5 to
35 000 pg/mL and the coefficient of variation (CV) was 9.3%
at a level of 126 pg/mL and 5.5% at 5319 pg/mL. hsTnT was
measured using the highly sensitive assay with a range of
values from 3 to 10 000 pg/mL. The CV was 6.0% at a level
of 26 pg/mL and 5.4% at 2140 pg/mL. The value at the 99th
percentile cutoff from a healthy reference population was
13 pg/mL for hsTnT with a 10% CV.13
Galectin-3, GDF-15, and SST2 were measured from EDTA
plasma stored at 70°C from samples at baseline in batch at
the University of Pennsylvania Laboratory. Galectin-3, GDF-
15, and SST2 were measured using ELISA and had intra-assay
CVs of 4.0%, 2.0%, and 2.6%, respectively.
Incident AF
Incident AF was defined as a hospitalization for AF and
confirmed by physician adjudication.24 At each study visit,
participants were asked if they had visited an emergency
department or had been hospitalized. Medical records from
corresponding hospitals or healthcare systems were queried
for qualifying encounters. Diagnostic codes for AF (Interna-
tional Classification of Diseases, Ninth Revision, Clinical
Modification 427.31 or 427.32) prompted retrieval of medical
records and centralized review for the ascertainment of
incident AF. Final adjudication of events was done after at
least 2 study physicians reviewed all possible AF events by
manual review of relevant medical records. Hospitalized ECGs
(when available) were reviewed and were part of the
adjudication process.
Baseline Assessments
Baseline information included sociodemographic characteris-
tics, anthropometric measurements, self-reported medical
history, current medications, and lifestyle behaviors. Diabetes
mellitus was defined as a fasting glucose >126 mg/dL, a
nonfasting glucose >200 mg/dL, or use of medications for
diabetes mellitus including insulin. Additional measurements
included 24-hour urine total protein, glucose, low-density
lipoprotein cholesterol, and high-density lipoprotein choles-
terol. Markers of abnormal mineral metabolism, including
fibroblast growth factor-23, serum phosphorus, and total PTH,
were used in multivariable models since prior studies have
shown an independent association between these markers
and AF risk.24
Echocardiograms were obtained in the entire study popu-
lation 1 year after the baseline visit, and measures included left
ventricular ejection fraction, left ventricular mass indexed to
body surface area, and left atrial diameter.25,26 Assessments
were performed using 2-dimensional echocardiographic images
and quantified at a central laboratory following a standard
imaging protocol from the American Society of Echocardiog-
raphy guidelines.27
Serum creatinine was measured using a standardized
enzymatic method at the CRIC central laboratory.28 Estima-
tion of GFR was calculated from serum creatinine (www.roc
he-diagnostics.us; CV 1.1%) using the Chronic Kidney Disease
Epidemiology Collaboration equation (CKD-EPI).29
Statistical Analysis
Descriptive statistics were used to summarize baseline
demographic and clinical characteristics by quintile (except
for hsTnT) of each cardiac biomarker, and crude-incident AF
rates per 1000 person-years were calculated.
In time to event analyses, participants were followed for
the first occurrence of an AF event. Censoring occurred at the
last follow-up time (because of death, lost to follow-up, or
administrative censoring). Separate Cox-regression methods
were used to evaluate the associations of NT-proBNP, hsTnT,
galectin-3, GDF-15, and SST2 continuously and categorically
using quintiles with incident AF. An exception was hsTnT,
which was analyzed in tertiles of the detectable range with
the reference category corresponding to an undetectable
range. The proportional hazards assumption was tested
through examination of the time-dependency of the Schoen-
feld partial residuals. Because of the skewed distribution of
cardiac biomarkers, the hazard ratio estimates in continuous
analyses were calculated assuming a log-log linear relation-
ship with incident AF. The functional form of the association
of incident AF and each cardiac biomarker was further
evaluated with penalized regression spline models with 3
degrees of freedom using the pspline command in the R
survival package.
Multivariable models were adjusted for covariates deemed
a-priori to be possibly associated with AF including clinical
center, age, sex, ethnicity, eGFR, 24-hour urinary protein,
systolic blood cholesterol, history of self-reported cardiovas-
cular disease including HF, use of angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers,
b-blockers, and diuretics.
Several sensitivity analyses were performed. To evaluate
the independence between biomarkers in their association
with AF, analyses were done with multivariable models
including all 5 cardiac biomarkers. Since cardiac biomarkers
may be surrogate markers of subclinical HF, analyses were
done with further statistical adjustment for echocardio-
graphic measures of left ventricular structure and function
(left ventricular mass index, left ventricular ejection fraction)
and left atrial diameter, and excluding participants with
prevalent HF. Finally, these cardiac biomarkers were mea-
sured 2 years after enrollment in a random subset of
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participants (N=790). We conducted a sensitivity analysis
that used time-updated biomarkers for this subset (and
baseline biomarkers only for the remaining participants) to
investigate whether more proximal cardiac biomarkers were
more strongly associated with incident AF.
All analyses were conducted using R 3.4.0 (R Foundation
for Computing, Vienna, Austria).
Results
Baseline Characteristics
Among 3053 participants, the median eGFR at baseline was
43 mL/min per 1.73 m2 and 24-hour urinary protein was
0.1 g/d. Compared with participants with NT-proBNP con-
centrations ≤32.7 pg/mL (lowest quintile-quintile used in
Table 1), participants in the highest quintile (>423 pg/mL)
were older (59 versus 53 years), more likely to be female
(45% versus 35%), to have diabetes mellitus (66% versus 33%),
prevalent HF (17% versus 2%), to be using diuretics (72%
versus 42%), and less likely to report current alcohol use (54%
versus 74%) (Table 1). Higher NT-proBNP concentrations were
associated with lower eGFR, higher 24-hour urine protein, and
higher blood pressure. These patterns were similar for hsTnT,
galectin-3, GDF-15, and SST-2 (Tables S1 through S4).
Demographic and clinical characteristics stratified by level
of kidney function are presented in Table S5.
Cardiac Biomarkers and Risk of Incident AF
NT-proBNP and hsTnT
During a median follow-up time of 8 years (interquartile range
5.4–9.4 years), an incident AF event was identified in 279
(9%) participants. There were strong unadjusted associations
between all evaluated cardiac biomarkers and incident AF
with spline models suggestive of log-linear associations
between NT-proBNP and incident AF (Figure).
In multivariable Cox-regression models, NT-proBNP and
hsTnT were each strongly and independently associated with
incident AF (Table 2). These associations were largely
unchanged when adding HF medication use and markers of
abnormal mineral metabolism (model 2) to multivariable
models that included clinical center, demographics, comor-
bidities, and level of kidney function. The hazard ratio (per 1
SD) for the association of higher baseline log-transformed NT-
proBNP with incident AF was 2.11 (95% CI, 1.75, 2.55), and
1.42 (95% CI, 1.20, 1.68) for log-transformed hsTnT. In
categorical analyses, we found a dose–response relationship
with a 7-fold hazard ratio for the highest NT-proBNP category,
and >2-fold for hsTnT, comparing the highest category with
the lowest (Table 2).
Galectin-3, GDF-15, and sST-2
In multivariable models, SST-2 was independently associated
with incident AF as a continuous predictor (Table 2). However,
this association was not observed in categorical analyses.
Galectin-3 and GDF-15 were not independently associated
with AF risk in continuous or in categorical analyses.
Sensitivity Analyses
Results from models that included all cardiac biomarkers were
consistent with results presented in the main analysis
(Table S6). Results were also consistent when adjusting for
echocardiographic measurements that included left ventricu-
lar ejection fraction, left ventricular mass index, and left atrial
diameter (Table S3). Similarly, time-variable analyses with
repeated measurements of cardiac biomarkers were consis-
tent with the primary results (Table S7). There were no
significant differences in the results when excluding 182
participants with prevalent HF (Table S8). Finally, results were
similar across 2 strata of eGFR using a cutoff of 45 mL/min
per 1.73 m2 (Table S9).
Discussion
In this prospective cohort study, we found strong, graded
associations between level of NT-proBNP and hsTnT with risk
of incident AF in a large population of participants with CKD.
These associations were independent of covariates known to
be predictive of AF in the general population and in people
with CKD, including measures of level of kidney function,
alterations in mineral metabolism, and left ventricular struc-
ture and function. Associations with incident AF were modest
and inconsistent for SST2 (only significant when SST2 was
modeled continuously) and not significant for galectin-3 and
GDF-15. Our findings suggest that increased atrial myocardial
stretch and myocardial cell injury are important factors
contributing to the high burden of AF in patients with CKD.
Our findings of strong associations of NT-proBNP and
incident AF are consistent with observations in the general
population.7 Both HF and hypertension have been shown to
increase the hemodynamic load to the atria causing myocardial
stretch, increasing the susceptibility to developing AF.6,30,31
This mechanism may be particularly important in patients with
CKD where subclinical volume overload is highly prevalent and
strongly correlated with NT-proBNP levels.32 Despite the strong
overlap between AF and HF, our results were consistent when
excluding participants with HF at baseline. It is therefore
possible that elevations in NT-proBNP are manifestations of
subclinical HF. Previously, we found that incident AF in people
with CKD is associated with a nearly 6-fold risk of developing
HF, an estimate higher than most recognized risk factors for
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HF.10 In CKD, therefore, AF and HF may be interrelated through
shared mechanistic pathways related to volume status, cardiac
filling pressures, and myocardial stress.
We also observed a strong association of the level of
hsTnT with the risk of incident AF. This finding is consistent
with a mechanism of high myocardial wall stress with
secondary subclinical myocardial ischemia and/or injury. In
the general population, hsTnT has been shown to be
independently associated with AF risk.8 Myocardial cell
damage causing elevations in hsTnT concentrations is a
Table 1. Demographic and Clinical Characteristics by Quintile of Baseline NT-proBNP (N=3053)
≤32.7 pg/mL
(N=611)
32.8 to 81
pg/mL (N=610)
81.1 to 176
pg/mL (N=611)
176.1 to 423
pg/mL (N=610)
>423
pg/mL (N=611)
Demographics
Age, y 52.7 (11.8) 56.8 (10.7) 58.2 (11.2) 59.0 (10.6) 59.1 (10.4)
Women 211 (35) 284 (47) 288 (47) 324 (53) 274 (45)
Race/ethnicity
Non-Hispanic white 269 (44) 269 (44) 281 (46) 274 (45) 202 (33)
Non-Hispanic black 271 (44) 250 (41) 235 (38) 211 (35) 241 (39)
Hispanic 40 (7) 59 (10) 80 (13) 99 (16) 143 (23)
Other 31 (5) 32 (5) 15 (2) 26 (4) 25 (4)
Medical history
Diabetes mellitus 202 (33) 260 (43) 277 (45) 325 (53) 406 (66)
History of CVD 73 (12) 115 (19) 152 (25) 199 (33) 316 (52)
History of heart failure 13 (2) 12 (2) 16 (3) 39 (6) 102 (17)
Current smoker 54 (9) 64 (10) 77 (13) 90 (15) 104 (17)
Alcohol use 451 (74) 430 (70) 382 (63) 376 (62) 327 (54)
Markers of kidney function
eGFR (CKD-EPI), mL/min per 1.73 m2 54.5 (14.1) 47.9 (13.7) 43.8 (13.8) 40.7 (12.8) 36.2 (12.6)
24-h urine protein, g/d, median (IQR) 0.1 (0.0–0.2) 0.1 (0.0–0.5) 0.1 (0.1–0.6) 0.2 (0.1–0.9) 0.8 (0.1–3.3)
Clinical characteristics and laboratory measurements
BMI, kg/m2 31.8 (6.7) 32.1 (7.6) 32.0 (8.5) 32.1 (8.5) 31.9 (7.5)
SBP, mm Hg 119.4 (15.7) 124.1 (18.5) 125.4 (19.0) 131.8 (22.3) 142.8 (25.7)
DBP, mm Hg 73.1 (11.3) 72.5 (11.5) 70.1 (11.8) 71.4 (13.3) 73.0 (15.6)
Hemoglobin, g/dL 13.6 (1.6) 12.9 (1.5) 12.6 (1.6) 12.3 (1.6) 11.7 (1.9)
LDL cholesterol, mg/dL 107.5 (33.5) 104.3 (34.9) 104.2 (35.0) 101.0 (33.9) 101.6 (37.8)
HDL cholesterol, mg/dL 47.3 (14.4) 47.9 (15.6) 49.2 (16.2) 48.5 (16.4) 46.4 (16.0)
FGF-23, RU/mL, median (IQR) 101.0 (74.1–145.4) 122.7 (85.9–182.6) 132.8 (97.2–208.3) 159.5 (108.8–244.6) 207.2 (131.4–341.6)
Serum phosphorus, mg/dL 3.5 (0.6) 3.6 (0.6) 3.7 (0.7) 3.8 (0.7) 4.0 (0.7)
Total PTH, pg/mL, median (IQR) 40.7 (29.4–56.2) 48.0 (33.0–78.8) 51.1 (32.0–82.4) 58.9 (37.9–95.2) 78.0 (47.2–127.0)
Medications
ACEi/ARBs 410 (67) 407 (67) 425 (70) 424 (70) 405 (66)
Diuretics 254 (42) 325 (53) 347 (57) 357 (59) 442 (72)
b-Blockers 142 (23) 212 (35) 263 (43) 362 (59) 418 (68)
Echocardiographic measurements
LVEF from echocardiogram 55.5 (6.4) 56.1 (6.0) 56.0 (6.9) 54.5 (8.3) 52.0 (9.4)
LVMI, g/m2 54.9 (18.0) 58.9 (19.5) 61.5 (21.8) 65.4 (21.8) 79.0 (25.8)
Data are mean (SD) or N (%), except as noted. ACEi/ARBs indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blockers; BMI, body mass index; CKD-EPI, Chronic
Kidney Disease Epidemiology Collaboration equation; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FGF-23, fibroblast growth
factor-23; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; NT-proBNP, N-
terminal pro-B-type natriuretic peptide; PTH, parathyroid hormone; SBP, systolic blood pressure.
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common finding in patients with HF with elevated cardiac
filling pressures, myocardial inflammatory states, and acute
myocardial pressure-overload, even in the absence of
obstructive epicardial coronary artery disease.33,34 Taken
together, the strong observed associations of NT-proBNP
and hsTnT with AF suggest that elevated filling pressures
with secondary myocardial injury, and possibly microvascular
ischemic disease, which are highly prevalent in patients with
CKD,35–38 may be important mechanisms for the onset of
AF.
In contrast to our observations for the associations
between NT-proBNP and hsTnT and AF risk, observations for
the association between galectin-3, GDF-15 and SST2, and
incident AF, were modest and inconsistent. These results
differ from studies conducted in the general population that
have found significant and consistent associations between
these markers and AF risk.17,18 Although these observations
do not serve as evidence for atrial inflammation, fibrosis, and
remodeling as pathways leading to AF in the setting of CKD,
our findings must be interpreted cautiously. We evaluated
factors associated with the first occurrence of AF, at which
time atrial remodeling may not have yet occurred. This is an
important consideration since atrial remodeling and fibrosis
may be the consequence of the cumulative exposure to AF
triggers.39 In addition, results from analyses of surrogate
biomarkers may not translate into predictable physiologic
processes.
We believe that these observations advance the knowledge
of the mechanisms leading to the disproportionate high
burden of AF in people with CKD and may inform future
therapeutic trials aimed at decreasing the high cardiovascular
risk experienced by these patients. For instance, our obser-
vations suggest that AF may be part of the same spectrum of
disorders as HF and the cardiorenal syndrome.40 It is
therefore possible that more judicious use of diuretics may
reduce the burden of AF in CKD. In addition, our study leads
Figure. Distribution and unadjusted associations of cardiac biomarkers and incident atrial fibrillation. GDF-15 indicates growth differentiation
factor-15; hsTnT, high-sensitivity troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; sST-2, soluble ST-2.
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Table 2. Associations of Cardiac Biomarkers and Incident AF in Participants With Chronic Kidney Disease
Cardiac Biomarker N at Risk (N events)
Model 1* Model 2†
HR (95% CI) P Value‡ HR (95% CI) P Value
Continuous predictors (per SD higher concentration)
Log-NT-proBNP 2.12 (1.77, 2.55) <0.0001 2.11 (1.75, 2.55) <0.0001
Log-hsTnT 1.51 (1.29, 1.77) <0.0001 1.42 (1.20, 1.68) <0.0001
Log-sST-2 1.4 (1.19, 1.64) <0.0001 1.35 (1.16, 1.58) 0.0001
Log-galectin-3 1.09 (0.94, 1.27) 0.26 1.05 (0.91, 1.22) 0.49
Log-GDF-15 1.28 (1.06, 1.53) 0.009 1.16 (0.96, 1.4) 0.14
Categorical predictors
NT-proBNP, pg/mL
(Reference: ≤2.7) 611 (17)
32.8–81 610 (36) 1.92 (1.08, 3.4) <0.0001 1.94 (1.09, 3.44) <0.0001
81.1–176 611 (44) 2.22 (1.26, 3.91) 2.27 (1.28, 4.03)
176.1–423 610 (74) 3.85 (2.22, 6.65) 4.02 (2.3, 7.02)
>423 611 (108) 7.12 (4.01, 12.63) 7.31 (4.05, 13.17)
hsTnT, pg/mL
(Reference: <10) 1019 (44)
10.1–15.6 669 (61) 1.58 (1.05, 2.37) 0.0001 1.54 (1.02, 2.33) 0.002
15.7–26.9 684 (81) 2.04 (1.35, 3.09) 1.97 (1.3, 2.96)
>26.9 681 (93) 2.8 (1.78, 4.4) 2.47 (1.55, 3.96)
sST-2, ng/mL
(Reference: ≤10.4) 611 (37)
10.5–13.5 611 (48) 1.07 (0.69, 1.65) 0.05 1.05 (0.67, 1.62) 0.13
13.6–17.1 611 (46) 1.05 (0.68, 1.63) 1.02 (0.65, 1.59)
17.2–22.7 609 (68) 1.39 (0.92, 2.11) 1.34 (0.88, 2.03)
>22.7 611 (80) 1.68 (1.09, 2.58) 1.55 (1, 2.4)
Galectin-3, ng/mL
(Reference: ≤9.27) 612 (46)
9.28–12.6 609 (55) 1.08 (0.73, 1.6) 0.39 1.05 (0.71, 1.56) 0.59
12.7–15.8 612 (48) 0.97 (0.64, 1.47) 0.91 (0.6, 1.38)
15.9–20.8 609 (59) 1.14 (0.76, 1.73) 1.07 (0.71, 1.61)
>20.8 611 (71) 1.4 (0.92, 2.12) 1.25 (0.82, 1.92)
GDF-15, pg/mL
(Reference: ≤880) 611 (24)
881–1250 610 (48) 1.52 (0.89, 2.6) 0.04 1.47 (0.86, 2.52) 0.27
1251–1670 612 (57) 1.43 (0.83, 2.46) 1.31 (0.76, 2.26)
1671–2370 609 (71) 1.89 (1.06, 3.39) 1.65 (0.93, 2.94)
>2370 611 (79) 2.36 (1.29, 4.3) 1.88 (1.02, 3.46)
SD for each predictor: NT-proBNP (1.68), hsTnT (0.82), sST-2 (0.57), galectin-3 (0.50), GDF-15 (0.59). AF indicates atrial fibrillation; FGF-23, fibroblast growth factor-23; GDF-15, growth
differentiation factor-15; hsTnT, high-sensitivity troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; sST-2, soluble ST-2.
*Model 1: Adjusted for age, age2, sex, race, site, diabetes mellitus, cardiovascular disease, smoking, 24-h urinary protein, estimated glomerular filtration rate, systolic blood pressure, body
mass index, low-density lipoprotein, high-density lipoprotein.
†Model 2: Adjusted for variables in model 1 plus angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, diuretics, b-blockers, phosphate, parathyroid hormone, FGF-23.
‡P values in categorical models are for differences between categories.
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to additional questions about whether novel therapies that
directly affect cardiorenal outcomes may be effective in
decreasing the risk of AF in patients with CKD.41,42 Specif-
ically, sodium-glucose-cotransporter-2 inhibitors have direct
hemodynamic effects because of significant reductions in
plasma volume reducing intracardiac filling pressures and
myocardial injury.43,44 Furthermore, our observation may help
identify patients at highest risk for cardiovascular disease who
would potentially derive most benefit from these interven-
tions. Finally, our study may inform future research aimed at
improving predictive models for the onset of AF in people with
CKD.
Important strengths of this study include the large and
well-characterized cohort of CKD participants. Incident AF
was systematically ascertained and rigorously adjudicated
using standardized criteria. All biomarkers were measured
concurrently. We controlled for a large set of possible
confounders, which included markers of mineral metabolism
and echocardiographic measures of heart structure and
function.
Limitations of our study include that we did not have
available rhythm monitoring measurements that would enable
us to identify the type of AF (eg, paroxysmal versus persistent
AF) or assess the arrhythmic AF burden (if paroxysmal)
present in patients newly diagnosed with AF. In addition, we
defined incident AF solely based on hospitalized cases.
Therefore, we did not capture cases occurring in outpatient
settings. It is likely that this resulted in an underestimation of
the true incidence of AF. Although in our analyses we
accounted for a large set of clinical characteristics, it is
possible that unmeasured confounding may in part account
for the observed results. Finally, the study sample consisted
of research volunteers followed in nephrology clinics, poten-
tially limiting the generalizability of these findings to all CKD
populations.
In conclusion, among patients with CKD, elevated NT-
proBNP and hsTnT were strongly and independently associated
with the risk of incident AF. There was a modest association of
SST2 with incident AF, which was not observed for galectin-3 or
GDF-15. These results provide further mechanistic insights into
the strong association between CKD and AF and may inform
future trials of therapeutic interventions aimed at reducing the
risk of AF in patients with CKD.
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Table S1. Demographic and clinical characteristics by quantile of baseline Galectin-3.  
 Overall ≤ 9.27 9.28 – 12.6 12.7 – 15.8 15.9 – 20.8 > 20.8 
N 3053 612 609 612 609 611 
Age (years) 57.1 (11.2) 55.2 (11.3) 57.0 (11.8) 57.0 (10.9) 57.8 (11.2) 58.7 (10.5) 
Women 1381 (45) 205 (33) 249 (41) 283 (46) 298 (49) 346 (57) 
Race/ethnicity       
Non-Hispanic white 1295 (42) 336 (55) 309 (51) 262 (43) 203 (33) 185 (30) 
Non-Hispanic black 1208 (40) 208 (34) 217 (36) 245 (40) 266 (44) 272 (45) 
Hispanic 421 (14) 41 (7) 61 (10) 77 (13) 109 (18) 133 (22) 
Other 129 (4) 27 (4) 22 (4) 28 (5) 31 (5) 21 (3) 
eGFR (CKD-EPI), 
mL/min/1.73m2 44.6 (14.8) 53.1 (14.2) 48.8 (14.5) 44.9 (13.4) 40.5 (12.4) 35.7 (12.8) 
24-hour urine protein 
(g/d), median 0.2 (0.1-0.8) 0.1 (0.0-0.3) 0.1 (0.0-0.6) 0.1 (0.1-0.7) 0.2 (0.1-1.1) 0.4 (0.1-2.0) 
Diabetes 1470 (48) 205 (33) 233 (38) 293 (48) 340 (56) 399 (65) 
History of CVD 855 (28) 125 (20) 152 (25) 168 (27) 182 (30) 228 (37) 
History of HF 182 (6) 18 (3) 29 (5) 31 (5) 39 (6) 65 (11) 
Current smoker 389 (13) 57 (9) 68 (11) 94 (15) 80 (13) 90 (15) 
Alcohol use 1966 (64) 460 (75) 428 (70) 388 (63) 347 (57) 343 (56) 
BMI (kg/m2) 32.0 (7.8) 30.4 (6.9) 31.5 (7.4) 32.0 (7.6) 32.8 (8.2) 33.1 (8.5) 
SBP (mmHg) 128.7 (22.1) 123.1 (19.3) 127.3 (21.5) 127.4 (22.0) 131.6 (22.8) 134.0 (23.0) 
DBP (mmHg) 72.0 (12.8) 73.0 (12.3) 72.0 (12.5) 72.2 (12.6) 72.2 (13.6) 70.8 (13.0) 
Hemoglobin (g/dL) 12.6 (1.8) 13.4 (1.7) 13.0 (1.6) 12.7 (1.7) 12.3 (1.7) 11.7 (1.7) 
LDL cholesterol (mg/dL) 103.7 (35.1) 105.0 (33.8) 105.5 (33.5) 104.2 (33.8) 102.8 (36.1) 101.1 (38.1) 
HDL cholesterol (mg/dL) 47.9 (15.8) 48.6 (15.5) 47.6 (15.8) 48.4 (16.3) 47.6 (15.0) 47.1 (16.3) 
ACEi/ARBs 2071 (68) 380 (62) 408 (67) 424 (69) 423 (69) 436 (71) 
Diuretics 1725 (57) 260 (42) 318 (52) 348 (57) 374 (61) 425 (70) 
Beta blockers 1397 (46) 227 (37) 263 (43) 270 (44) 314 (52) 323 (53) 
FGF-23 (RU/mL), median 138.6 (94.3-
225.3) 
100.4 (72.3-
147.4) 
123.6 (84.9-
186.2) 
138.7 (95.9-
205.9) 
156.8 (107.3-
250.7) 
207.1 (129.6-
349.3) 
Serum phosphorus, mg/dL 3.7 (0.7) 3.5 (0.6) 3.6 (0.6) 3.7 (0.6) 3.8 (0.7) 4.0 (0.7) 
 
 
Total PTH (pg/mL), 
median 
52.7 (34.0-
88.0) 39.5 (29.0-61.3) 45.0 (31.2-74.8) 51.8 (34.9-83.9) 60.5 (38.9-99.7) 
76.0 (46.0-
131.2) 
EF from echocardiogram 54.9 (7.6) 55.0 (7.4) 55.5 (7.3) 55.4 (7.4) 54.4 (8.1) 54.4 (7.6) 
LVMI 63.2 (22.7) 57.3 (20.2) 62.2 (22.2) 62.9 (22.2) 66.3 (23.9) 68.8 (23.7) 
Entries are mean (SD) or N (%), except as noted. 
  
 
 
Table S2. Demographic and clinical characteristics by quantile of baseline hsTnT.  
 < 10 10.1 – 15.6 15.7 –  26.9 > 26.9 
N 1019 669 684 681 
Age (years) 57.1 (11.2) 53.4 (11.8) 58.7 (10.8) 59.8 (9.9) 
Women 1381 (45) 657 (64) 301 (45) 250 (37) 
Race/ethnicity     
Non-Hispanic white 1295 (42) 513 (50) 323 (48) 268 (39) 
Non-Hispanic black 1208 (40) 356 (35) 243 (36) 286 (42) 
Hispanic 421 (14) 96 (9) 75 (11) 105 (15) 
Other 129 (4) 54 (5) 28 (4) 25 (4) 
eGFR (CKD-EPI), 
mL/min/1.73m2 44.6 (14.8) 51.8 (15.3) 45.0 (12.6) 41.8 (12.8) 
24-hour urine protein (g/d), 
median 0.2 (0.1-0.8) 0.1 (0.0-0.3) 0.1 (0.1-0.4) 0.2 (0.1-1.0) 
Diabetes 1470 (48) 250 (25) 290 (43) 380 (56) 
History of CVD 855 (28) 153 (15) 163 (24) 247 (36) 
History of HF 182 (6) 17 (2) 29 (4) 49 (7) 
Current smoker 389 (13) 131 (13) 89 (13) 85 (12) 
Alcohol use 1966 (64) 722 (71) 443 (66) 433 (63) 
BMI (kg/m2) 32.0 (7.8) 30.8 (7.6) 31.7 (7.7) 33.0 (8.1) 
SBP (mmHg) 128.7 (22.1) 120.9 (18.1) 126.9 (20.6) 131.9 (22.4) 
DBP (mmHg) 72.0 (12.8) 72.3 (11.6) 71.5 (12.3) 71.6 (13.7) 
Hemoglobin (g/dL) 12.6 (1.8) 13.0 (1.6) 12.8 (1.8) 12.6 (1.8) 
LDL cholesterol (mg/dL) 103.7 (35.1) 108.2 (33.4) 103.4 (33.5) 99.6 (34.2) 
HDL cholesterol (mg/dL) 47.9 (15.8) 51.5 (16.1) 48.0 (16.0) 45.5 (15.3) 
ACEi/ARBs 2071 (68) 583 (57) 467 (70) 521 (76) 
Diuretics 1725 (57) 401 (39) 375 (56) 450 (66) 
Beta blockers 1397 (46) 332 (33) 316 (47) 368 (54) 
FGF-23 (RU/mL), median 138.6 (94.3-225.3) 111.9 (78.2-171.0) 133.1 (93.8-211.0) 148.5 (100.7-229.7) 
Serum phosphorus, mg/dL 3.7 (0.7) 3.6 (0.6) 3.6 (0.6) 3.7 (0.7) 
Total PTH (pg/mL), median 52.7 (34.0-88.0) 43.0 (31.0-65.9) 46.8 (32.0-78.0) 60.0 (37.8-91.0) 
EF from echocardiogram 54.9 (7.6) 56.0 (6.3) 55.7 (7.6) 54.5 (8.0) 
 
 
LVMI 63.2 (22.7) 53.3 (16.8) 61.5 (18.9) 67.7 (23.6) 
Entries are mean (SD) or N (%), except as noted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S3. Demographic and clinical characteristics by quantile of baseline GDF-15.  
 ≤ 880 881 – 1250 1251 – 1670 1671 – 2370 > 2370 
N 611 610 612 609 611 
Age (years) 57.1 (11.2) 50.9 (11.7) 56.3 (11.1) 58.5 (10.7) 59.9 (9.9) 
Women 1381 (45) 301 (49) 285 (47) 269 (44) 276 (45) 
Race/ethnicity      
Non-Hispanic white 1295 (42) 343 (56) 276 (45) 258 (42) 239 (39) 
Non-Hispanic black 1208 (40) 206 (34) 236 (39) 253 (41) 250 (41) 
Hispanic 421 (14) 37 (6) 66 (11) 84 (14) 92 (15) 
Other 129 (4) 25 (4) 32 (5) 17 (3) 28 (5) 
eGFR (CKD-EPI), 
mL/min/1.73m2 44.6 (14.8) 58.9 (12.8) 48.6 (12.0) 42.9 (11.3) 38.7 (12.2) 
24-hour urine protein (g/d), 
median 0.2 (0.1-0.8) 0.1 (0.0-0.2) 0.1 (0.0-0.4) 0.1 (0.1-0.6) 0.3 (0.1-1.4) 
Diabetes 1470 (48) 101 (17) 227 (37) 312 (51) 388 (64) 
History of CVD 855 (28) 59 (10) 130 (21) 184 (30) 229 (38) 
History of HF 182 (6) 13 (2) 23 (4) 32 (5) 48 (8) 
Current smoker 389 (13) 38 (6) 46 (8) 81 (13) 108 (18) 
Alcohol use 1966 (64) 484 (79) 430 (70) 374 (61) 345 (57) 
BMI (kg/m2) 32.0 (7.8) 30.9 (7.3) 32.0 (7.9) 32.9 (7.9) 32.4 (7.9) 
SBP (mmHg) 128.7 (22.1) 119.9 (17.9) 124.6 (19.2) 128.2 (20.9) 133.4 (23.0) 
DBP (mmHg) 72.0 (12.8) 74.0 (11.7) 73.1 (12.6) 71.1 (12.7) 71.4 (13.4) 
Hemoglobin (g/dL) 12.6 (1.8) 13.6 (1.5) 13.1 (1.6) 12.6 (1.6) 12.1 (1.6) 
LDL cholesterol (mg/dL) 103.7 (35.1) 111.4 (33.3) 105.7 (34.0) 103.1 (34.9) 101.2 (36.1) 
HDL cholesterol (mg/dL) 47.9 (15.8) 50.4 (16.3) 48.8 (15.6) 47.0 (15.0) 47.0 (16.0) 
ACEi/ARBs 2071 (68) 329 (54) 429 (70) 442 (72) 457 (75) 
Diuretics 1725 (57) 211 (35) 306 (50) 377 (62) 396 (65) 
Beta blockers 1397 (46) 176 (29) 259 (42) 285 (47) 329 (54) 
FGF-23 (RU/mL), median 138.6 (94.3-225.3) 90.6 (66.8-123.3) 116.8 (84.4-166.1) 142.7 (103.3-207.0) 173.1 (121.8-268.4) 
Serum phosphorus, mg/dL 3.7 (0.7) 3.4 (0.5) 3.6 (0.6) 3.7 (0.6) 3.8 (0.7) 
Total PTH (pg/mL), median 52.7 (34.0-88.0) 38.0 (28.9-53.0) 44.8 (31.8-67.9) 54.7 (35.2-83.2) 67.0 (40.8-105.2) 
EF from echocardiogram 54.9 (7.6) 55.2 (6.8) 55.2 (7.4) 55.4 (7.5) 54.7 (8.1) 
 
 
LVMI 63.2 (22.7) 53.2 (18.0) 60.5 (21.8) 65.0 (21.9) 67.6 (23.5) 
Entries are mean (SD) or N (%), except as noted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S4. Demographic and clinical characteristics by quantile of SST-2. 
 ≤ 10.4 10.5 – 13.5 13.6 – 17.1 17.2 – 22.7 > 22.7 
N 611 611 611 609 611 
Age (years) 57.1 (11.2) 55.3 (12.0) 57.5 (10.4) 57.9 (10.8) 58.3 (10.8) 
Women 1381 (45) 382 (63) 324 (53) 274 (45) 222 (36) 
Race/ethnicity      
Non-Hispanic white 1295 (42) 234 (38) 274 (45) 258 (42) 267 (44) 
Non-Hispanic black 1208 (40) 280 (46) 259 (42) 244 (40) 221 (36) 
Hispanic 421 (14) 64 (10) 56 (9) 80 (13) 98 (16) 
Other 129 (4) 33 (5) 22 (4) 29 (5) 23 (4) 
eGFR (CKD-EPI), 
mL/min/1.73m2 44.6 (14.8) 47.7 (15.2) 45.1 (14.9) 45.4 (14.7) 43.4 (14.4) 
24-hour urine protein (g/d), 
median 0.2 (0.1-0.8) 0.1 (0.0-0.3) 0.1 (0.1-0.4) 0.1 (0.1-0.7) 0.2 (0.1-1.3) 
Diabetes 1470 (48) 202 (33) 244 (40) 281 (46) 359 (59) 
History of CVD 855 (28) 117 (19) 160 (26) 162 (27) 200 (33) 
History of HF 182 (6) 35 (6) 32 (5) 30 (5) 38 (6) 
Current smoker 389 (13) 88 (14) 79 (13) 81 (13) 71 (12) 
Alcohol use 1966 (64) 419 (69) 392 (64) 391 (64) 375 (62) 
BMI (kg/m2) 32.0 (7.8) 31.5 (7.9) 32.7 (7.7) 32.3 (7.5) 32.0 (8.1) 
SBP (mmHg) 128.7 (22.1) 123.5 (20.5) 126.4 (20.8) 128.5 (21.6) 132.1 (23.4) 
DBP (mmHg) 72.0 (12.8) 72.5 (12.7) 72.1 (12.6) 71.8 (12.7) 71.9 (13.2) 
Hemoglobin (g/dL) 12.6 (1.8) 12.8 (1.6) 12.7 (1.7) 12.6 (1.7) 12.6 (1.8) 
LDL cholesterol (mg/dL) 103.7 (35.1) 106.6 (34.4) 104.7 (32.9) 103.2 (34.0) 103.4 (35.6) 
HDL cholesterol (mg/dL) 47.9 (15.8) 48.7 (15.1) 47.9 (15.1) 48.0 (15.4) 46.4 (14.8) 
ACEi/ARBs 2071 (68) 370 (61) 411 (67) 420 (69) 436 (72) 
Diuretics 1725 (57) 299 (49) 331 (54) 336 (55) 373 (61) 
Beta blockers 1397 (46) 244 (40) 250 (41) 274 (45) 314 (52) 
FGF-23 (RU/mL), median 138.6 (94.3-225.3) 123.1 (83.7-201.3) 137.8 (95.6-210.2) 131.4 (91.1-201.3) 146.4 (97.0-236.6) 
Serum phosphorus, mg/dL 3.7 (0.7) 3.7 (0.6) 3.7 (0.6) 3.7 (0.6) 3.7 (0.7) 
Total PTH (pg/mL), median 52.7 (34.0-88.0) 50.0 (32.5-78.2) 49.9 (33.8-82.8) 48.4 (33.0-81.5) 56.0 (36.0-91.0) 
EF from echocardiogram 54.9 (7.6) 55.6 (7.9) 55.4 (7.2) 54.9 (7.5) 54.6 (7.6) 
 
 
LVMI 63.2 (22.7) 59.0 (22.0) 62.3 (22.3) 63.5 (22.7) 65.6 (22.4) 
Entries are mean (SD) or N (%), except as noted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S5. Demographic and clinical characteristics by kidney function.  
 Overall 
N = 3053 
eGFR < 30 
N = 543 
eGFR 30- <45 
N = 1091 
eGFR 45- <60 
N = 954 
eGFR ≥60 
N = 465 
Demographics      
Age (years) 57.1 (11.2) 57.9 (11.4) 59.0 (11.1) 57.6 (10.4) 50.9 (10.8) 
Women 1381 (45) 265 (49) 516 (47) 387 (41) 213 (46) 
Race/ethnicity      
Non-Hispanic white 1295 (42) 179 (33) 436 (40) 439 (46) 241 (52) 
Non-Hispanic black 1208 (40) 221 (41) 446 (41) 374 (39) 167 (36) 
Hispanic 421 (14) 119 (22) 171 (16) 95 (10) 36 (8) 
Other 129 (4) 24 (4) 38 (3) 46 (5) 21 (5) 
Medical history       
Diabetes 1470 (48) 305 (56) 590 (54) 423 (44) 152 (33) 
History of CVD 855 (28) 183 (34) 353 (32) 248 (26) 71 (15) 
History of heart failure 182 (6) 54 (10) 77 (7) 38 (4) 13 (3) 
Current smoker 389 (13) 73 (13) 154 (14) 102 (11) 60 (13) 
Alcohol use 1966 (64) 311 (57) 646 (59) 661 (69) 348 (75) 
Markers of Kidney 
function      
eGFR (CKD-EPI); 
mL/min/1.73m2 44.6 (14.8) 24.6 (3.7) 37.9 (4.3) 51.8 (4.3) 69.0 (8.4) 
24-hour urine protein (g/d), 
median (IQR) 0.2 (0.1-0.8) 0.7 (0.2-2.4) 0.2 (0.1-1.1) 0.1 (0.0-0.4) 0.1 (0.0-0.2) 
Clinical characteristics 
and laboratory 
measurements      
BMI (kg/m2) 32.0 (7.8) 32.1 (8.1) 32.3 (7.7) 31.8 (7.9) 31.3 (7.4) 
SBP (mmHg) 128.7 (22.1) 133.5 (24.5) 130.4 (22.5) 127.1 (20.5) 122.2 (19.4) 
DBP (mmHg) 72.0 (12.8) 71.2 (13.6) 71.2 (12.7) 72.5 (12.4) 74.0 (12.8) 
Hemoglobin (g/dL) 12.6 (1.8) 11.7 (1.6) 12.4 (1.7) 13.0 (1.7) 13.4 (1.6) 
LDL cholesterol (mg/dL) 103.7 (35.1) 101.8 (37.5) 102.1 (35.1) 104.3 (34.4) 108.6 (33.1) 
HDL cholesterol (mg/dL) 47.9 (15.8) 46.3 (15.2) 47.0 (15.1) 48.8 (16.2) 49.7 (16.7) 
 
 
FGF-23 (RU/mL), median 
(IQR) 138.6 (94.3-225.3) 241.9 (169.7-377.8) 156.3 (109.4-238.5) 115.7 (82.3-164.6) 91.7 (67.6-120.3) 
Serum phosphorus, mg/dL 3.7 (0.7) 4.1 (0.8) 3.8 (0.6) 3.5 (0.6) 3.5 (0.5) 
Total PTH (pg/mL), median 
(IQR) 52.7 (34.0-88.0) 104.0 (64.4-174.9) 60.0 (39.0-93.0) 44.0 (31.0-65.0) 35.5 (27.3-48.6) 
Medications      
ACEi/ARBs 2071 (68) 364 (67) 797 (73) 670 (70) 240 (52) 
Diuretics 1725 (57) 378 (70) 699 (64) 478 (50) 170 (37) 
Beta blockers 1397 (46) 297 (55) 554 (51) 407 (43) 139 (30) 
Echocardiographic 
measurements      
LVEF from echocardiogram 54.9 (7.6) 54.5 (7.9) 54.8 (7.7) 55.2 (7.4) 55.1 (7.2) 
LVMI (g/m2) 63.2 (22.7) 71.4 (23.6) 65.4 (23.4) 60.8 (21.1) 55.4 (20.3) 
 
Cells are mean (SD) or N (%), except as noted.                                                                                                                                                              
 
NT-proBNP (N-terminal pro-B-type natriuretic peptide); CVD (cardiovascular disease); eGFR (estimated glomerular filtration 
rate); BMI (body mass index); SBP (systolic blood pressure); DBP (diastolic blood pressure); LDL (low-density 
lipoprotein); HDL (high-density lipoprotein); PTH (parathyroid hormone); ACEi/ARBs (angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker); LVEF (left ventricular ejection fraction); LVMI (left ventricular mass index).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S6. Associations of cardiac biomarkers and incident atrial fibrillation in the CRIC Study, adjusting for alternative 
cardiac biomarkers and echocardiographic measures. 
Cardiac Biomarker  Final model* Final model + adjustment for 
alternative cardiac 
biomarkers † 
 
Final model + adjustment for 
echocardiographic 
measurements ‡ 
 
 N at risk 
(N 
events) HR (95% CI) p-value HR (95% CI) p-value 
HR (95% CI) p-value 
Continuous predictors        
Log(Galectin-3) per 1 
SD (0.50) increase 
 
1.05 (0.91, 1.22) 0.49 1.06 (0.91, 1.23) 0.44 1.06 (0.91, 1.23) 0.49 
Log(NT-proBNP) per 1 
SD (1.68) increase 
 
2.11 (1.75, 2.55) < 0.0001 2.08 (1.72, 2.52) < 0.0001 1.86 (1.52, 2.26) < 0.0001 
Log(hsTnT) per 1 SD 
(0.82) increase 
 
1.42 (1.20, 1.68) < 0.0001 1.35 (1.14, 1.61) 0.0007 1.31 (1.09, 1.56) 0.003 
Log(GDF-15) per 1 SD 
(0.59) increase 
 
1.16 (0.96, 1.40) 0.14 1.09 (0.89, 1.33) 0.42 1.14 (0.94, 1.39) 0.18 
Log(SST-2) per 1 SD 
(0.57) increase 
 
1.35 (1.16, 1.58) 0.0001 1.29 (1.11, 1.51) 0.001 1.35 (1.16, 1.59) 0.0001 
Categorical predictors        
Galectin-3         
(Reference: ≤ 9.27) 612 (46)       
9.28 – 12.6 609 (55) 1.05 (0.71, 1.56) 0.59 1.08 (0.72, 1.62) 0.56 1.03 (0.68, 1.54) 0.67 
12.7 – 15.8 612 (48) 0.91 (0.60, 1.38)  0.92 (0.60, 1.41)  0.93 (0.61, 1.41)  
15.9 – 20.8 609 (59) 1.07 (0.71, 1.61)  1.08 (0.71, 1.63)  1.07 (0.71, 1.62)  
> 20.8 611 (71) 1.25 (0.82, 1.92)  1.29 (0.84, 1.98)  1.25 (0.81, 1.94)  
NT-proBNP, pg/mL        
(Reference: ≤ 32.7) 611 (17)       
32.8 – 81 610 (36) 1.94 (1.09, 3.44) < 0.0001 1.94 (1.09, 3.46) < 0.0001 1.87 (1.05, 3.32) < 0.0001 
81.1 – 176 611 (45) 2.27 (1.28, 4.03)  2.27 (1.28, 4.04)  2.03 (1.14, 3.62)  
176.1 – 423 610 (74) 4.02 (2.30, 7.02)  4.00 (2.29, 7.01)  3.59 (2.05, 6.28)  
> 423 611 (108) 7.31 (4.05, 
13.17)  
7.27 (4.02, 
13.15)  
5.43 (2.94, 
10.03)  
hsTnT, pg/mL        
(Reference: < 10) 1019 (44)       
10.1 – 15.6 669 (61) 1.54 (1.02, 2.33) 0.002 1.54 (1.02, 2.33) 0.005 1.45 (0.96, 2.19) 0.05 
15.7 – 26.9 684 (81) 1.97 (1.30, 2.96)  1.93 (1.27, 2.91)  1.69 (1.11, 2.57)  
> 26.9 681 (93) 2.47 (1.55, 3.96)  2.33 (1.44, 3.76)  1.94 (1.19, 3.15)  
 
 
GDF-15        
(Reference: ≤ 880) 611 (24)       
881 – 1250  610 (48) 1.47 (0.86, 2.52) 0.27 1.49 (0.87, 2.55) 0.45 1.43 (0.84, 2.45) 0.31 
1251 – 1670  612 (57) 1.31 (0.76, 2.26)  1.33 (0.77, 2.30)  1.30 (0.75, 2.25)  
1671 – 2370  609 (71) 1.65 (0.93, 2.94)  1.64 (0.91, 2.95)  1.62 (0.90, 2.93)  
> 2370 611 (79) 1.88 (1.02, 3.46)  1.71 (0.91, 3.24)  1.85 (0.99, 3.44)  
sST-2        
(Reference: ≤ 10.4) 611 (37)       
10.5 – 13.5  611 (48) 1.05 (0.67, 1.62) 0.13 1.06 (0.68, 1.65) 0.21 1.08 (0.69, 1.69) 0.11 
13.6 – 17.1 611 (46) 1.02 (0.65, 1.59)  1.01 (0.65, 1.58)  1.10 (0.70, 1.71)  
17.2 – 22.7 609 (68) 1.34 (0.88, 2.03)  1.33 (0.88, 2.02)  1.40 (0.92, 2.14)  
> 22.7 611 (80) 1.55 (1.00, 2.40)  1.49 (0.96, 2.33)  1.64 (1.06, 2.55)  
*Final model: age, age2, sex, race, site, diabetes, CVD, smoking, 24h urinary protein, eGFR, SBP, BMI, LDL, HDL plus ACEi/ARBs, 
diuretics, beta blockers, phosphate, PTH, FGF-23                                                                                                                                                                                                                         
†Final model plus other biomarkers (NT pro-BP, Galectin-3, hsTnT, GDF-15, sST-2)                                                                                                                                          
‡Final model plus LVMI, LVEF, and left atrial diameter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S7. Time-updated associations of cardiac biomarkers with incident atrial fibrillation. 
Cardiac Biomarker Model 1* Model 2† Model 3 ‡ 
 HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Continuous predictors       
Log(Galectin-3) per 1 SD 
(0.50) increase 
1.10 (0.94, 1.29) 0.24 1.04 (0.85, 1.26) 0.71 1.03 (0.85, 1.26) 0.73 
Log(NT-proBNP) per 1 SD 
(1.68) increase 2.19 (1.85, 2.60) 
< 0.0001 
2.52 (2.03, 3.14) < 0.0001 2.45 (1.96, 3.08) < 0.0001 
Log(hsTnT) per 1 SD (0.82) 
increase 1.45 (1.26, 1.66) 
< 0.0001 
1.44 (1.18, 1.77) 0.0005 1.36 (1.10, 1.68) 0.005 
Log(GDF-15) per 1 SD (0.59) 
increase 1.26 (1.05, 1.52) 0.01 1.26 (1.00, 1.59) 0.048 1.19 (0.93, 1.52) 0.16 
Log(SST-2) per 1 SD (0.57) 
increase 1.28 (1.09, 1.50) 0.003 1.43 (1.19, 1.72) 0.0001 1.33 (1.10, 1.60) 0.003 
Categorical predictors       
Galectin-3        
(Reference: ≤ 9.27)       
9.28 – 12.6 1.27 (0.81, 1.99) 0.17 1.06 (0.66, 1.73) 0.31 1.09 (0.67, 1.76) 0.32 
12.7 – 15.8 1.01 (0.63, 1.62)  0.77 (0.45, 1.32)  0.78 (0.46, 1.33)  
15.9 – 20.8 1.4 (0.88, 2.22)  1.06 (0.64, 1.75)  1.05 (0.63, 1.75)  
> 20.8 1.60 (1.00, 2.57)  1.34 (0.79, 2.27)  1.33 (0.78, 2.27)  
NT-proBNP, pg/mL       
(Reference: ≤ 32.7)       
32.8 – 81 1.57 (0.80, 3.06) < 0.0001 2.00 (0.90, 4.45) < 0.0001 2.04 (0.92, 4.53) < 0.0001 
81.1 – 176 2.01 (1.06, 3.81)  2.97 (1.37, 6.45)  3.01 (1.39, 6.55)  
176.1 – 423 3.52 (1.90, 6.53)  5.76 (2.72, 12.19)  5.81 (2.73, 12.38)  
> 423 6.88 (3.68, 12.86)  11.41 (5.18, 25.17)  11.33 (5.12, 25.07)  
hsTnT, pg/mL       
(Reference: < 10)       
10.1 – 15.6 1.60 (1.02, 2.51) 0.0001 1.80 (1.06, 3.03) 0.003 1.81 (1.07, 3.06) 0.008 
15.7 – 26.9 2.19 (1.41, 3.42)  2.42 (1.42, 4.13)  2.38 (1.39, 4.08)  
> 26.9 2.79 (1.76, 4.43)  3.02 (1.65, 5.54)  2.81 (1.50, 5.25)  
GDF-15       
(Reference: ≤ 880)       
881 – 1250  1.30 (0.75, 2.27) 0.10 1.80 (0.88, 3.66) 0.24 1.80 (0.88, 3.70) 0.34 
1251 – 1670  1.20 (0.69, 2.10)  1.70 (0.83, 3.50)  1.73 (0.83, 3.60)  
1671 – 2370  1.73 (0.96, 3.12)  2.24 (1.05, 4.80)  2.25 (1.03, 4.89)  
> 2370 1.95 (1.05, 3.59)  2.48 (1.10, 5.60)  2.26 (0.96, 5.35)  
SST-2       
 
 
(Reference: ≤ 10.4)       
10.5 – 13.5  1.17 (0.74, 1.85) 0.24 1.50 (0.85, 2.62) 0.09 1.53 (0.87, 2.69) 0.16 
13.6 – 17.1 1.10 (0.69, 1.74)  1.16 (0.65, 2.07)  1.17 (0.65, 2.09)  
17.2 – 22.7 1.35 (0.87, 2.09)  1.66 (0.96, 2.87)  1.64 (0.95, 2.85)  
> 22.7 1.59 (1.01, 2.50)  1.97 (1.12, 3.49)  1.85 (1.04, 3.31)  
*Model 1: age, age2, sex, race, site, diabetes, CVD, smoking, 24h urinary protein, eGFR, SBP, BMI, LDL, HDL                                                                                     
†Model 2: Model 1 plus ACEi/ARBs, diuretics, beta blockers, phosphate, PTH, FGF-23                                                                                                                               
‡Model 3: Model 2 plus other biomarkers (NT pro-BP, Gal3, hsTnT, GDF-15, SST-2)               
 
 
  
 
 
Table S8. Associations of cardiac biomarkers and incident atrial fibrillation, excluding participants with prevalent 
HF (N = 2871).  
Cardiac Biomarker  Model 1* Model 2† 
 N at risk  
(N events) HR (95% CI) p-value HR (95% CI) p-value 
Continuous predictors 
(per SD higher 
concentration) 
 
    
Log-NT-proBNP   2.10 (1.73, 2.55) < 0.0001 2.10 (1.72, 2.57) < 0.0001 
Log-hsTnT   1.50 (1.27, 1.76) < 0.0001 1.41 (1.18, 1.68) 0.0001 
Log-SST-2   1.38 (1.18, 1.63) 0.0001 1.34 (1.14, 1.57) 0.0004 
Log-Galectin-3   1.10 (0.94, 1.29) 0.25 1.06 (0.90, 1.24) 0.48 
Log-GDF-15   1.31 (1.09, 1.58) 0.005 1.19 (0.98, 1.45) 0.09 
Categorical predictors      
NT-proBNP, pg/mL      
(Reference: ≤ 32.7) 598 (17)     
32.8 – 81 598 (34) 1.84 (1.03, 3.29) < 0.0001 1.86 (1.04, 3.32) < 0.0001 
81.1 – 176 595 (44) 2.33 (1.32, 4.11)  2.38 (1.34, 4.25)  
176.1 – 423 571 (65) 3.72 (2.12, 6.51)  3.92 (2.21, 6.93)  
> 423 509 (90) 7.21 (4.00, 13.00)  7.44 (4.05, 13.70)  
hsTnT, pg/mL      
(Reference: < 10) 1002 (44)     
10.1 – 15.6 640 (55) 1.51 (0.99, 2.30) 0.0002 1.50 (0.98, 2.29) 0.002 
15.7 – 26.9 635 (75) 2.10 (1.37, 3.21)  2.04 (1.34, 3.12)  
> 26.9 594 (76) 2.76 (1.71, 4.44)  2.46 (1.50, 4.03)  
SST-2, ng/ml      
(Reference: ≤ 10.4) 576 (33)     
10.5 – 13.5  579 (43) 1.11 (0.69, 1.76) 0.07 1.09 (0.68, 1.73) 0.15 
13.6 – 17.1 581 (43) 1.13 (0.71, 1.78)  1.09 (0.69, 1.73)  
17.2 – 22.7 571 (63) 1.52 (0.98, 2.36)  1.45 (0.94, 2.25)  
> 22.7 564 (68) 1.74 (1.10, 2.75)  1.61 (1.01, 2.57)  
Galectin-3, ng/ml      
(Reference: ≤ 9.27) 594 (43)     
 
 
9.28 – 12.6 580 (51) 1.11 (0.74, 1.67) 0.34 1.09 (0.72, 1.64) 0.57 
12.7 – 15.8 581 (42) 0.95 (0.62, 1.47)  0.90 (0.58, 1.40)  
15.9 – 20.8 570 (54) 1.21 (0.79, 1.85)  1.13 (0.73, 1.73)  
> 20.8 546 (60) 1.44 (0.92, 2.24)  1.28 (0.82, 2.00)  
GDF-15, pg/ml      
(Reference: ≤ 880) 598 (23)     
881 – 1250  587 (44) 1.64 (0.95, 2.84) 0.02 1.61 (0.93, 2.80) 0.16 
1251 – 1670  580 (54) 1.64 (0.94, 2.84)  1.53 (0.88, 2.66)  
1671 – 2370  561 (61) 2.08 (1.15, 3.77)  1.84 (1.02, 3.33)  
> 2370 545 (68) 2.72 (1.47, 5.02)  2.21 (1.18, 4.14)  
 
NT-proBNP (N-terminal pro-B-type natriuretic peptide), hsTnT (high sensitivity troponin T), SST-2 (soluble ST-2), GDF-15 
(growth differentiation factor-15).                                                                                                                                      
Standard deviation for each predictor: NT-proBNP (1.68), hsTnT (0.82), SST-2 (0.57), galectin-3 (0.50), GDF-15 (0.59)               
*Model 1: Adjusted for age, age2, sex, race, site, diabetes, CVD, smoking, 24h urinary protein, eGFR, SBP, BMI, LDL, 
HDL.                                           
 †Model 2: Adjusted for variables in model 1 plus ACEi/ARBs, diuretics, beta blockers, phosphate, PTH, FGF-23.        
 
  
 
 
Table S9. Associations of cardiac biomarkers and incident atrial fibrillation, by eGFR category. 
 
Cardiac Biomarker Model 1* Model 2† 
 HR (95% CI) p-value HR (95% CI) p-value 
Continuous 
predictors (per SD 
higher concentration)     
eGFR ≥ 45 (N=1634)     
Log-NT-proBNP  2.39 (1.77, 3.22) < 0.0001 2.35 (1.76, 3.15) < 0.0001 
Log-hsTnT  1.70 (1.33, 2.17) < 0.0001 1.62 (1.25, 2.09) 0.0002 
Log-SST-2  1.43 (1.11, 1.83) 0.005 1.39 (1.09, 1.77) 0.008 
Log-Galectin-3  1.19 (0.93, 1.52) 0.17 1.15 (0.91, 1.47) 0.25 
Log-GDF-15  1.20 (0.94, 1.53) 0.14 1.11 (0.88, 1.41) 0.38 
eGFR < 45 (N=1619)     
Log-NT-proBNP  1.98 (1.59, 2.45) < 0.0001 1.97 (1.58, 2.46) < 0.0001 
Log-hsTnT  1.44 (1.21, 1.71) < 0.0001 1.33 (1.10, 1.61) 0.003 
Log-SST-2  1.39 (1.15, 1.68) 0.0008 1.34 (1.11, 1.60) 0.002 
Log-Galectin-3  1.03 (0.86, 1.24) 0.72 0.99 (0.82, 1.19) 0.92 
Log-GDF-15  1.34 (1.07, 1.68) 0.01 1.19 (0.94, 1.51) 0.16 
 
NT-proBNP (N-terminal pro-B-type natriuretic peptide), hsTnT (high sensitivity troponin T), SST-2 (soluble ST-2), GDF-15 
(growth differentiation factor-15).                                                                                                                                      
Standard deviation for each predictor: NT-proBNP (1.68), hsTnT (0.82), SST-2 (0.57), galectin-3 (0.50), GDF-15 (0.59)               
*Model 1: Adjusted for age, age2, sex, race, site, diabetes, CVD, smoking, 24h urinary protein, eGFR, SBP, BMI, LDL, 
HDL.                                          
  †Model 2: Adjusted for variables in model 1 plus ACEi/ARBs, diuretics, beta blockers, phosphate, PTH, FGF-23.        
                                                                                                                   
